



WBB Securities, LLC

Press Release

WBB is Sole Placement Agent for \$13 million Neoprobe Corporation Financing

SAN DIEGO, CA and WESTFIELD, NJ

December 27, 2007 -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it had signed definitive agreements for a \$13 million financing with Platinum Montaur Life Sciences LLC ("Montaur"). WBB Securities LLC served as the sole placement agent on the transaction with Montaur.

The first funding under the Securities Purchase Agreement between Neoprobe and Montaur is for \$7 million, which will be used to repay in full \$5.7 million in notes that were due in January 2009. In addition, funding from the first closing will retire 10,125,000 in warrants to purchase shares of Neoprobe common stock that were associated with the notes due in 2009. Montaur has committed to additional funding aggregating \$6 million that will be used to support the development of Lymphoseek®, a proprietary radioactive tracing agent being developed for use in connection with gamma detection devices in a surgical procedure known as Intraoperative Lymphatic Mapping.

David Bupp, Neoprobe President and CEO said, "We are pleased to complete this financing with Montaur, which provides Neoprobe with the financial resources to complete clinical and other development activities associated with Lymphoseek."

Michael Goldberg, M.D., Principal, Montaur Capital Partners, LLC and Portfolio Manager of the Platinum Montaur Life Sciences Fund, said, "Neoprobe represents an excellent investment opportunity. The company has established a dominant position in the gamma detection medical device arena, structured a Lymphoseek marketing and distribution agreement with Cardinal Health, and is poised to commence the Phase III clinical evaluation of Lymphoseek that we believe will transform the company's revenue and profitability outlook."

M. LaRae Bakerink, WBB Securities CEO said, "WBB Securities is pleased to have acted as the sole placement agent in this transaction. Neoprobe's existing line of hand-held gamma detection devices plus the prospects for Lymphoseek make the company a leader in its field."

Steve Brozak, President of WBB Securities said, "This agreement will give Neoprobe the resources it needs to bring the first FDA-approved lymph node mapping agent to market. Such a product could be a significant breakthrough for cancer patients."

About WBB Securities

Headquartered in San Diego, CA, with offices in Westfield, NJ, WBB Securities, LLC is an independent broker/dealer, specializing in order execution, healthcare research, banking and back office operations. With its nationwide team of senior investment and research professionals, the WBB Securities Trading and Operations Team provides transaction and compliance services

PRESS RELEASE – WBB Securities is Sole Placement Agent for \$13 million Neoprobe Corporation Financing

to its broker team. WBB Securities Research is a leader in Biotech, Medical Device, and Pharmaceutical industry research. Further information about WBB Securities can be found on its Web site at www.wbbsec.com

About Neoprobe Corporation

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000[®] line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix[®] line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[®] and RIGScan[®] CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

* * *

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Neoprobe's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Neoprobe's products are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Neoprobe's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. WBB Securities undertakes no obligation to publicly update or revise any forward-looking statements.